Outer membrane vesicles of Neisseria lactamica as a potential mucosal adjuvant

Vaccine

Volumn 24, Issue 2, 2006, Pages 206-214

  Sardiñas, Gretel ^a,b   Reddin, Karen ^c   Pajon, Rolando ^a,b   Gorringe, Andrew ^c  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b Centre for Emergency Preparedness and Response ^*  (Cuba)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Adjuvant; Mucosal; Neisseria

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; OUTER MEMBRANE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CROSS REACTION; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INFECTION PREVENTION; MENINGOCOCCOSIS; MOUSE; MUCOSAL IMMUNITY; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; NEISSERIA LACTAMICA;

EID: 28644439710     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.07.064     Document Type: Article

References (52)

1. J.R. McGhee, J. Mestecky, M.T. Dertzbaugh, J.H. Eldridge, M. Hirasawa, and H. Kiyono The mucosal immune system: from fundamental concepts to vaccine development Vaccine 10 1992 75 88
2. P.L. Ogra, H. Faden, and R.C. Welliver Vaccination strategies for mucosal immune responses Clin Microbiol Rev 14 2001 430 445
3. G. Dietrich, M. Griot-Wenk, I.C. Metcalfe, A.B. Lang, and J.F. Viret Experience with registered mucosal vaccines Vaccine 21 2003 678 683
4. M. Pizza, M.M. Giuliani, M.R. Fontana, E. Monaci, G. Douce, and G. Dougan Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants Vaccine 19 2001 2534 2541
5. M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, and T. Linder Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland N Engl J Med 350 2004 896 903
6. G. Bjune, E.A. Hoiby, J.K. Gronnesby, O. Arnesen, J.H. Fredriksen, and A. Halstensen Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway Lancet 338 1991 1093 1096
7. G.V. Sierra, H.C. Campa, N.M. Varcacel, N.T. Hidalgo, H.A. Barbosa, and C.T. Sacchi Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba NIPH Ann 14 1991 195 207
8. J.C. de Moraes, B.A. Perkins, M.C. Camargo, N.T. Hidalgo, H.A. Barbosa, and C.T. Sacchi Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil Lancet 340 1992 1074 1078
9. B. Haneberg, R. Dalseg, F. Oftung, E. Wedege, E.A. Hoiby, and I.L. Haugen Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant Dev Biol Stand 92 1998 127 133
10. R. Dalseg, E. Wedege, J. Holst, I.L. Haugen, E.A. Høiby, and B. Haneberg Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice Vaccine 17 1999 2336 2345
11. H. Bakke, K. Lie, I.L. Haugen, G.E. Korsvold, E.A. Hoiby, and L.M. Naess Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance Infect Immun 69 2001 5010 5015
12. H. Bakke, T.N. Setek, P.N. Huynh, I.L. Haugen, E.A. Høiby, and J. Holst Immunisation schedules for non-replicating nasal vaccines can be made simple by allowing time for development of immunological memory Vaccine 22 2004 2278 2284
13. T. Guthrie, S.Y. Wong, B. Liang, S. Hou, E.A. Hoiby, and S.R. Andersen Local and systemic antibody responses in mice immunized intranasally with native and detergent-extracted outer membrane vesicles from Neisseria meningitidis Infect Immun 72 2004 2528 2537
14. B. Haneberg, R. Dalseg, E. Wedege, E.A. Hoiby, I.L. Haugen, and F. Oftung Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans Infect Immun 66 1998 1334 1341
15. J.L. Drabick, B.L. Brandt, E.E. Moran, N.B. Saunders, D.R. Shoemaker, and W.D. Zollinger Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers Vaccine 18 1999 160 172
16. F. Oftung, L.M. Naess, L.M. Wetzler, G.E. Korsvold, A. Aase, and E.A. Hoiby Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine Infect Immun 67 1999 921 927
17. K.L. Katial, B.L. Brandt, E.E. Moran, S. Marks, V. Agnello, and W.D. Zollinger Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine Infect Immun 70 2002 702 707
18. A. Aase, L.M. Naess, R.H. Sandin, T.K. Herstad, F. Oftung, and J. Holst Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease Vaccine 21 2003 2042 2051
19. F. Estevez, A. Carr, L. Solorzano, O. Valiente, C. Mesa, and O. Barroso Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP) Vaccine 18 1999 190 197
20. K. Oliver, K. Reddin, P. Bracegirdle, M.J. Hudson, R. Borrow, and I.M. Feavers Neisseria lactamica protects against experimental meningococcal infection Infect Immun 70 2002 3621 3626
21. S. Sanchez, G. Troncoso, C.M. Ferreiros, and M.T. Criado Evaluation of cross-reactive antigens as determinants of cross-bactericidal activity in pathogenic and commensal Neisseria Vaccine 19 2001 3390 3398
22. S. Sanchez, G. Troncoso, M.T. Criado, and C. Ferreiros In vitro induction of memory-driven responses against Neisseria meningitidis by priming with Neisseria lactamica Vaccine 20 2002 2957 2963
23. C.A. O'dwyer, K. Reddin, D. Martin, S.C. Taylor, A.R. Gorringe, and M.J. Hudson Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential Infect Immun 72 2004 6511 6518
24. D. Shouval Hepatitis B vaccines J Hepatol 39 2003 S70 S76
25. D.J. West, and G.B. Calandra Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination Vaccine 11 1996 1019 1027
26. E. Hardy, E. Martinez, D. Diago, R. Diaz, D. Gonzalez, and L. Herrera Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris J Biotechnol 77 2000 157 167
27. M. Isaka, Y. Yasuda, M. Mizokami, S. Kozuka, T. Taniguchi, and K. Matano Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant Vaccine 19 2001 1460 1466
28. A. Debin, R. Kravtzoff, J.V. Santiago, L. Cazales, S. Sperandio, and K. Melber Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses Vaccine 20 2002 2752 2763
29. M.J. McCluskie, R.D. Weeratna, P.J. Payette, and H.L. Davis Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA FEMS Immunol Med Microbiol 32 2002 179 185
30. F.G. Mackinnon, R. Borrow, A.R. Gorringe, A.J. Fox, D.M. Jones, and A. Robinson Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model Microb Pathog 15 1993 359 366
31. C.E. Frasch, L. van Alphen, J. Holst, J.T. Poolman, and E. Rosenqvist Outer membrane protein vesicle vaccines for meningococcal disease A.J. Pollard M.C.J. Maiden Methods in molecular medicine, vol 66. Meningococcal vaccines: methods and protocols 2001 Human Press Totawa, NJ, USA 81 107
32. S.E. Maslanka, L.L. Gheesling, D.E. Libutti, K.B. Donaldson, H.S. Harakeh, and J.K. Dykes Standardization and multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays Clin Diagn Lab Immunol 4 1997 156 167
33. K. Saukkonen Experimental meningococcal meningitis in the infant rat Microb Pathog 4 1988 203 211
34. M. Toropainen, L. Saarinen, P. van der Ley, B. Buipers, and H. Käyhty Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7, 16 subtype variants in an infant rat infection model Microb Pathog 30 2001 139 148
35. A.R. Gorringe, K.M. Reddin, S.G. Funnell, L. Johansson, A. Rytkönen, and A.-B. Jonsson Experimental disease models for the assessment of meningococcal vaccines Vaccine 23 2005 2214 2217
36. K. Cartwright, R. Morris, H. Rumke, A. Fox, R. Borrow, and N. Begg Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins Vaccine 17 1999 2612 2619
37. R. Gold, I. Goldschneider, M.L. Lepow, T.F. Draper, and M. Randolph Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children J Infect Dis 137 1978 112 121
38. J.M. Griffiss Mechanisms of host immunity K. Cartwright Meningococcal disease 1995 John Wiley and Sons Chichester, UK 35 70
39. T. Tonjum, and M. Koomey The pilus colonization factor of pathogenic neisserial species: organelle biogenesis and structure/function relationships - a review Gene 192 1997 155 163
40. D.B. Gill, and J.P. Atkinson CD46 in Neisseria pathogenesis Trends Mol Med 10 2004 459 465
41. S.D. Gray-Owen Neisserial Opa proteins: impact on colonization, dissemination and immunity Scand J Infect Dis 35 2003 614 618
42. A.B. Schryvers, and I. Stojiljkovic Iron acquisition systems in the pathogenic Neisseria Mol Microbiol 32 1999 1117 1123
43. L. Johansson, A. Rytkonen, P. Bergman, B. Albiger, H. Kallstrom, and T. Hokfelt CD46 in meningococcal disease Science 301 2003 373 375
44. C. Tang, R. Moxon, and M.M. Levine For discussion: live attenuated vaccines for group B meningococcus Vaccine 1999 114 117
45. P.G. Coen, K. Cartwright, and J. Stuart Mathematical modelling of infection and disease due to Neisseria meningitidis and Neisseria lactamica Int J Epidemiol 29 2000 180 188
46. L. Stevceva, and W. Strober Mucosal HIV vaccines: where are we now? Curr HIV Res 2 2004 1 10
47. H. Kiyono, and S. Fukuyama NALT- versus Peyer's-patch-mediated mucosal immunity Nat Rev Immunol 4 2004 699 710
48. T. Rodriguez, O. Perez, N. Menager, S. Ugrinovic, G. Bracho, and P. Mastroeni Interactions of proteoliposomes from serogroup B Neisseria meningitidis with bone marrow-derived dendritic cells and macrophages: adjuvant effects and antigen delivery Vaccine 23 2005 1312 1321
49. C. Mesa, J. De Leon, K. Rigley, and L.E. Fernandez Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation Vaccine 22 2004 3045 3052
50. P. Balmer, and R. Borrow Serologic correlates of protection for evaluating the response to meningococcal vaccines Expert Rev Vaccines 3 2004 77 87
51. D. West, K. Reddin, M. Matheson, R. Heath, S. Funnell, and M. Hudson Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection Infect Immun 69 2001 1561 1567
52. J.A. Welsch, G.R. Moe, R. Rossi, J. Adu-Bobie, R. Rappuoli, and D.M. Granoff Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity J Infect Dis 188 2003 1730 1740